Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability
and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will
have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale
for a subsequent clinical trial to utilize EPO in combination with everolimus as a more
successful pathway toward tolerance.